|
|
 Home 
What is Buprenorphine?
DATA Physician Locator
DATA 2000
FAQs
Notices
Links
En Español
 Physician Waiver Qualifications
Waiver Notification Form
Upcoming Trainings
Waived Physician WebBoard
Update Physician Contact Information
Model State Medical Board Policy
 Buprenorphine Summits
Articles
SAMHSA Reports
Other Gov't Reports
 Nurses Guide to Buprenorphine
 Email Us |
The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000 (DATA 2000) expands the clinical context of medication-assisted opioid addiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the Controlled Substances Act. moreSAMHSA Sponsored Buprenorphine Physician Clinical Support System (PCSS)The SAMHSA-funded PCSS is a national network of trained physician mentors with expertise in buprenorphine treatment and skilled in clinical education designed to assist practicing physicians in incorporating into their practices the treatment of prescription opioid and heroin dependent patients using buprenorphine.—www.pcssmentor.org 
Teva Announces Buprenorphine HCl Sublingual Tablets ApprovalOn Friday, May 7, 2010, Teva Pharmaceuticals USA announced that the U.S. Food and Drug Administration has granted final approval for the Company’s Abbreviated New Drug Application (“ANDA”) for Buprenorphine HCl Sublingual Tablets 2 & 8 mg. Teva’s Buprenorphine HCl Sublingual Tablets are the AB-rated generic equivalent of Reckitt Benckiser’s Subutex® and are indicated for the treatment of narcotic addiction.Teva intends the commercial launch to occur later this month. To learn more about Buprenorphine HCl Sublingual Tablets prescribing information, please call 1-800-227-7522. From Medscape Medical News
May 24, 2010 (New Orleans, Louisiana) — In persons dependent on prescription opioids, tapering with buprenorphine during a 9-month period, whether initially or after a period of substantial improvement, led to nearly universal relapse in the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study, presented here at the American Psychiatric Association 2010 Annual Meeting.
Click here for the article. Note: In order to access this article you will need to sign up for a FREE MedScape account, if you do not have one already.
|
 Treatment Improvement Protocol Increase Patient Limits 2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program 2006 Report On Diversion and Abuse of Buprenorphine Drug Enforcement Administraton (DEA) DATA Physician Locator  SAMHSA and DEA issue letter on prescribing Suboxone/Subutex in opioid treatment programs CSAT Director Informs Physicians of Increase in Patient Limits CSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program Locator CSAT Director Advises Physicians of Concerns Regarding Buprenorphine CSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator Follow this RealMedia link to view a Public Service Announcement (PSA) on office-based opioid addiction treatment featuring former Surgeon General Dr. C. Everett Koop. [Realplayer file, need Realplayer to review] If you do not have RealPlayer, you may download a free copy from Real Networks. Mozilla Firefox |
 |
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov * Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program. |
 |
